Shelton Capital Management Biogen Inc. Transaction History

Shelton Capital Management

  • $3.62 Billion
  • Q2 2024

A detailed history of Shelton Capital Management transactions in Biogen Inc. stock. As of the latest transaction made, Shelton Capital Management holds 21,301 shares of BIIB stock, worth $4.15 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
21,301
Previous 21,189 0.53%
Holding current value
$4.15 Million
Previous $4.57 Million 8.08%
% of portfolio
0.14%
Previous 0.13%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$190.52 - $236.72 $21,338 - $26,512
112 Added 0.53%
21,301 $4.94 Million
Q1 2024

May 15, 2024
BUY
$212.02 - $267.71 $4.49 Million - $5.67 Million
21,189 New
21,189 $4.57 Million
Q4 2023

Feb 14, 2024
BUY
$222.59 - $267.94 $119,753 - $144,151
538 Added 2.61%
21,189 $5.48 Million
Q3 2023

Nov 14, 2023
BUY
$253.3 - $285.89 $5.23 Million - $5.9 Million
20,651 New
20,651 $5.31 Million
Q2 2023

Aug 10, 2023
SELL
$275.25 - $318.06 $624,817 - $721,996
-2,270 Reduced 11.68%
17,163 $4.89 Million
Q1 2023

May 11, 2023
BUY
$256.56 - $292.34 $3.24 Million - $3.69 Million
12,633 Added 185.78%
19,433 $5.4 Million
Q4 2022

Feb 13, 2023
SELL
$252.44 - $306.72 $4.17 Million - $5.06 Million
-16,512 Reduced 70.83%
6,800 $1.88 Million
Q3 2022

Nov 14, 2022
BUY
$194.69 - $268.46 $964,883 - $1.33 Million
4,956 Added 27.0%
23,312 $6.22 Million
Q2 2022

Aug 11, 2022
SELL
$187.54 - $223.02 $37,508 - $44,604
-200 Reduced 1.08%
18,356 $3.74 Million
Q1 2022

May 12, 2022
SELL
$193.77 - $244.14 $19,377 - $24,414
-100 Reduced 0.54%
18,556 $3.91 Million
Q3 2021

Nov 15, 2021
BUY
$282.99 - $369.05 $17,828 - $23,250
63 Added 0.34%
18,656 $5.28 Million
Q2 2021

Aug 12, 2021
SELL
$259.0 - $414.71 $5.57 Million - $8.91 Million
-21,493 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$242.95 - $284.63 $5.22 Million - $6.12 Million
21,493 New
21,493 $6.01 Million
Q4 2020

Feb 16, 2021
SELL
$236.26 - $355.63 $105,371 - $158,610
-446 Reduced 3.23%
13,356 $3.27 Million
Q3 2020

Nov 09, 2020
SELL
$264.77 - $305.71 $191,693 - $221,334
-724 Reduced 4.98%
13,802 $3.92 Million
Q2 2020

Aug 12, 2020
SELL
$258.66 - $342.55 $321,255 - $425,447
-1,242 Reduced 7.88%
14,526 $3.89 Million
Q1 2020

May 13, 2020
SELL
$268.85 - $341.04 $6.77 Million - $8.59 Million
-25,174 Closed
0 $0
Q4 2019

Feb 11, 2020
BUY
$220.06 - $304.07 $1.82 Million - $2.52 Million
8,278 Added 48.99%
25,174 $7.47 Million
Q3 2019

Nov 13, 2019
BUY
$217.44 - $243.88 $3.67 Million - $4.12 Million
16,896 New
16,896 $3.93 Million
Q2 2019

Aug 14, 2019
BUY
$219.29 - $241.72 $3.45 Million - $3.8 Million
15,730 Added 318.68%
20,666 $4.83 Million
Q1 2019

May 10, 2019
SELL
$216.71 - $338.96 $3.37 Million - $5.27 Million
-15,545 Reduced 75.9%
4,936 $20.9 Million
Q4 2018

Jan 31, 2019
SELL
$278.5 - $352.75 $5.8 Million - $7.35 Million
-20,824 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$293.51 - $383.83 $14,088 - $18,423
-48 Reduced 0.23%
20,824 $7.36 Million
Q2 2018

Aug 10, 2018
BUY
$257.52 - $306.91 $5.37 Million - $6.41 Million
20,872 New
20,872 $6.06 Million
Q1 2018

May 15, 2018
BUY
$260.13 - $367.91 $453,666 - $641,635
1,744 Added 9.14%
20,824 $5.7 Million
Q4 2017

Feb 06, 2018
SELL
$307.64 - $344.58 $5.89 Million - $6.59 Million
-19,137 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
1,354 Added 7.61%
19,137 $5.19 Million
Q1 2017

Nov 28, 2017
BUY
N/A
1,813 Added 11.35%
17,783 $4.86 Million
Q3 2016

Dec 06, 2017
BUY
N/A
15,970 New
15,970 $5 Million
Q3 2016

Dec 04, 2017
BUY
N/A
15,970
15,970 $4.53 Million

Others Institutions Holding BIIB

# of Institutions
1,050
Shares Held
128M
Call Options Held
1.22M
Put Options Held
1.4M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $28B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Shelton Capital Management Portfolio

Follow Shelton Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email